Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

Silwan Chedid, Edgardo Rivera, Debbie K. Frye, Nuhad Ibrahim, Francisco Esteva, Vicente Valero, Gabriel Hortobagyi, Karl L. Mettinger, Massimo Cristofanilli

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences